Topical pain management with the 5 lidocaine medicated plaster a review

Current Medical Research and Opinion

Volumn 28, Issue 6, 2012, Pages 937-951

  Mick, Gérard ^a,b   Correa Illanes, Gerardo ^c,d  

^a HÔPITAL NEUROLOGIQUE   (France)

^b General Hospital   (France)

^c HOSPITAL DEL TRABAJADOR   (Chile)

^d UNIVERSITY OF CHILE   (Chile)

Author keywords

5 lidocaine medicated plaster; Chronic pain; Neuropathic pain; Pain management; Topical pain treatment

Indexed keywords

ANALGESIC AGENT; GABAPENTIN; LIDOCAINE; MORPHINE; PREGABALIN; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL WALL HERNIA; ALLODYNIA; ANALGESIA; APPLICATION SITE REACTION; ARTHRITIS; BRIEF PAIN INVENTORY; BURNING SENSATION; CANCER PAIN; CARPAL TUNNEL SYNDROME; CHRONIC PAIN; COMPLEX REGIONAL PAIN SYNDROME; DERMATITIS; DIABETIC NEUROPATHY; DISEASE SEVERITY; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; GERMAN PAIN DIARY; GERMAN PAIN QUESTIONNAIRE; HERNIOPLASTY; HERPES ZOSTER; HUMAN; HYPERALGESIA; KNEE OSTEOARTHRITIS; LAPAROSCOPIC SURGERY; LONG TERM CARE; LOW BACK PAIN; MULTICENTER STUDY (TOPIC); MYOFASCIAL PAIN; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NERVE INJURY; NEUROPATHIC PAIN; NEUROPATHIC PAIN SCALE; NUMERICAL RATING SCALE; ORTHOPEDIC SURGERY; OSTEOARTHRITIS; PAIN ASSESSMENT; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PROSTATECTOMY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SENSORY NEUROPATHY; SKIN MANIFESTATION; SPINAL CORD INJURY; TREATMENT DURATION; VISUAL ANALOG SCALE;

ADMINISTRATION, TOPICAL; ANESTHETICS, LOCAL; BANDAGES, HYDROCOLLOID; HUMANS; LIDOCAINE; NEURALGIA; NEURALGIA, POSTHERPETIC; OSMOLAR CONCENTRATION; PAIN MANAGEMENT; TREATMENT OUTCOME;

EID: 84862572874     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.690339     Document Type: Review

References (81)

1. Langley PC. The prevalence, correlates and treatment of pain in the European Union. Curr Med Res Opin 2011;27:463-80.
2. American Academy of Pain Medicine. AAPM facts and figures on pain. Available at: http://www.painmed.org/patient/facts.html [Last accessed 13 March 2011]
3. Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-333.
4. Schmader KE, Baron R, Haanpää ML, et al. Treatment considerations for elderly and frail patients with neuropathic pain. Mayo Clin Proc 2010;85(Suppl):S26-32.
5. Varrassi G, Müller-Schwefe G, Pergolizzi J, et al. Pharmacological treatment of chronic pain-the need for CHANGE. Curr Med Res Opin 2010;26:1231-45.
6. Dworkin RH, O'Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(Suppl 3):S3-14.
7. Attal N, Cruccu G, Baron R, et al EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-e88.
8. Davies PS, Galer BS. Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs 2004;64:937-47.
9. Garnock-Jones KP, Keating GM. Lidocaine 5% medicated plaster. A review of its use in postherpetic neuralgia. Drugs 2009;69:2149-65.
10. Electronic Medicines Compendium. Versatis 5% medicated plaster. Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/ medicine/19291 [Last accessed 1 March 2012]
11. Campbell BJ, Rowbotham M, Davies PS, et al. Systemic absorption of topical lidocaine in normal volunteers, patients with post-herpetic neuralgia, and patients with acute herpes zoster. J Pharm Sci 2002;91:1343-50.
12. Rowbotham MC, Davies PS, Verkempinck C, et al. Lidocaine patch: double-blind controlled study of a new treatment method for post-herpetic neuralgia. Pain 1996;65:39-44.
13. Baron R, Mayoral V, Leijon G, et al. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study. Curr Med Res Opin 2009;25:1663-76.
14. Gammaitoni AR, Alvarez NA, Galer BS. Pharmacokinetics and safety of continuously applied lidocaine patches 5%. Am J Health-Syst Pharm 2002;59:2215-20.
15. Baliki MN, Geha PY, Jabakhanji R, et al. A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis. Mol Pain 2008;4:47.
16. Krumova EK, Zeller M, Westermann A, et al. Lidocaine patch (5%) produces a selective, but incomplete block of Ad and C fibers. Pain 2012;153:273-80.
17. Wasner G, Kleinert A, Binder A, et al. Postherpetic neuralgia: topical lidocaine is effective in nociceptor-deprived skin. J Neurol 2005;252:677-86.
18. Gustorff B, Hauer D, Thaler J, et al. Antihyperalgesic efficacy of 5% lidocaine medicated plaster in capsaicin and sunburn pain models-two randomized, double-blinded, placebo-controlled crossover trials in healthy volunteers. Expert Opin Pharmacother 2011;12:2781-90.
19. Herrmann DN, Panoni V, Barbano RL, et al. Skin biopsy and quantitative sensory testing do not predict response to lidocaine patch in painful neuropathies. Muscle Nerve 2006;33:42-8.
20. Gammaitoni AR, Davis MW. Pharmacokinetics and tolerability of lidocaine patch 5% with extended dosing. Ann Pharmacother 2002;36:236-40.
21. Johnson RW, Wasner G, Saddier P, et al. Herpes zoster and postherpetic neuralgia. Optimizing management in the elderly patient. Drugs Aging 2008;25:991-1006.
22. Galer BS, Rowbotham MC, Perander J, et al. Topical lidocaine patch relieves postherpetic neuralgia more effectively than a vehicle topical patch: results of an enriched enrolment study. Pain 1999;80:533-8.
23. Binder A, Bruxelle J, Rogers P, et al. Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial. Clin Drug Investig 2009;29:393-408.
24. Rehm S, Binder A, Baron R. Post-herpetic neuralgia: 5% lidocaine medicated plaster, pregabalin, or a combination of both? A randomized, open, clinical effectiveness study. Curr Med Res Opin 2010;26:1607-19.
25. Baron R, Mayoral V, Leijon G, et al. Efficacy and safety of combination therapy with 5% lidocaine medicated plaster and pregabalin in post-herpetic neuralgia and diabetic polyneuropathy. Curr Med Res Opin 2009;25:1677-87.
26. Clère F, Delorme-Morin C, George B, et al. 5% lidocaine medicated plaster in elderly patients with postherpetic neuralgia-results of a compassionate use programme in France. Drugs Aging 2011;28:693-702.
27. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009;35:206-13.
28. Tesfaye S, Selvarajah D. Recent advances in the pharmacological management of painful diabetic neuropathy. Br J Diabetes Vasc Dis 2009;9:283-7.
29. White WT, Patel N, Drass M, et al. Lidocaine patch 5% with systemic analgesics such as gabapentin: a rational polypharmacy approach for the treatment of chronic pain. Pain Med 2003;4:321-30.
30. Barbano RL, Herrmann DN, Hart-Gouleau S, et al. Effectiveness, tolerability, and impact on quality of life of the 5% lidocaine patch in diabetic polyneuro-pathy. Arch Neurol 2004;61:914-18.
31. Argoff CE, Galer BS, Jensen MP, et al. Effectiveness of the lidocaine patch 5% on pain qualities in three chronic pain states: assessment with the Neuropathic Pain Scale. Curr Med Res Opin 2004;20(Suppl 2):S21-8.
32. Macrae WA. Chronic post-surgical pain: 10 years on. Br J Anaesth 2008;101:77-86.
33. Shipton E. Post-surgical neuropathic pain. ANZ J Surg 2008;78:548-55.
34. Hans G, Joukes E, Verhulst J, et al. Management of neuropathic pain after surgical and non-surgical trauma with lidocaine 5% patches: study of 40 consecutive cases. Curr Med Res Opin 2009;25:2737-43.
35. Meier T, Faust M, Hüppe M, et al. Reduction of chronic pain for non-post-herpetic peripheral neuropathies after topical treatment with a lidocaine patch [in German]. Schmerz 2004;18:172-8.
36. Meier T, Wasner G, Faust M, et al Efficacy of lidocaine patch 5% in the treatment of focal peripheral neuropathic pain syndromes: a randomized, double-blind, placebo-controlled study. Pain 2003;106:151-8.
37. Wasner G, Naleschinski D, Baron R. A role for peripheral afferents in the pathophysiology and treatment of at-level neuropathic pain in spinal cord injury? A case report. Pain 2007;131:219-25
38. Hans GH, Robert DN, Van Maldeghem KN. Treatment of an acute severe central neuropathic pain syndrome by topical application of lidocaine 5% patch: a case report. Spinal Cord 2008;46:311-13
39. Nayak S, Cunliffe M. Lidocaine 5% patch for localized chronic neuropathic pain in adolescents: report of five cases. Paediatr Anaesth 2008;18:554-8.
40. Habib AS, Polascik TJ, Weizer AZ, et al. Lidocaine patch for postoperative analgesia after radical retropubic prostatectomy. Anesth Analg 2009;108:1950-3.
41. Brabant S, Nagels W. Topical lidocaine 5% patch for the treatment of chronic postsurgical neuropathic skin pain. Pain Pract 2009;9(S1):35(PA62)
42. Saber AA, Elgamal MH, Rao AJ, et al. Early experience with lidocaine patch for postoperative pain control after laparoscopic ventral hernia repair. Int J Surg 2009;7:36-8.
43. Fleming JA, O'Connor BD. Use of lidocaine patches for neuropathic pain in a comprehensive cancer centre. Pain Res Manag 2009;14:381-8.
44. Correa-Illanes G, Calderón W, Roa R, et al. Treatment of localized post-traumatic neuropathic pain in scars with 5% lidocaine medicated plaster. Local Regional Anesth 2010;3:77-83.
45. Nicolaou A, Nicholson B, Hans G, et al. Outcome predictors for treatment success with 5% lidocaine medicated plaster in low back pain with neuropathic components and neuropathic pain after surgical and nonsurgical trauma. J Pain Res 2011;4:25-38.
46. Zink KA, Mayberry JC, Peck EG, et al. Lidocaine patches reduce pain in trauma patients with rib fractures. Am Surg 2011;77:438-42.
47. Nafissi A, Husain S, Ahmed T, et al. Lidoderm effectiveness in reducing pain in post-operative unilateral knee replacement patients. J Pain 2011;12(4 Suppl):P53.
48. Devers A, Galer BS. Topical lidocaine patch relieves a variety of neuropathic pain conditions: an open-label study. Clin J Pain 2000;16:205-8.
49. Berman SM, Justis JC, Ho MI. Lidocaine patch 5%-a novel, effective therapeutic approach to the treatment of HIV-associated painful peripheral neuropathy. Int Conf AIDS 2002;14: abstract ThPeB7380
50. Herrmann DN, Barbano RL, Hart-Gouleau S, et al An open-label study of the lidocaine patch 5% in painful idiopathic sensory polyneuropathy. Pain Med 2005;6:379-84.
51. Wilhelm IR, Tzabazis A, Likar R, et al. Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster. Eur J Anaesthesiol 2010;27:169-73.
52. Kern KU, Kohl M, Kiefer RT. Lidocaine patch for therapy of neuropathic and non-neuropathic pain: a clinical case series of 87 patients [in German]. Nervenarzt 2010;81:1490-7
53. Frost SG. Treatment of complex regional pain syndrome type 1 in a pediatric patient using the lidocaine patch 5%: a case report. Curr Ther Res 2003;64:626-9
54. Karmarkar A, Lieberman I. Management of complex regional pain syndrome type II using lidoderm 5% patches. Br J Anaesth 2007;98:261-2.
55. Vidal MA, Calderón E, Torres LM. Lidocaine patch for the treatment of CRPS in the arm by transcutaneous block of the brachial plexus. Clinical case [in Spanish]. Rev Soc Esp Dolor 2007;5:351-4
56. Cheville AL, Sloan JA, Northfelt DW, et al. Use of a lidocaine patch in the management of postsurgical neuropathic pain in patients with cancer: a phase III double-blind crossover study (N01CB). Support Care Cancer 2009;17:451-60.
57. Nalamachu S, Crockett RS, Mathur D. Lidocaine patch 5% for carpal tunnel syndrome: how it compares with injections: a pilot study. J Fam Pract 2006;55:209-14.
58. Nalamachu S, Crockett RS, Gammaitoni AR, et al. A comparison of the lido-caine patch 5% vs naproxen 500 mg twice daily for the relief of pain associated with carpal tunnel syndrome: a 6-week, randomized, parallel-group study. Med Gen Med 2006;8:33.
59. Dalpiaz AS, Lordon SP, Lipman AG. Topical lidocaine patch therapy for myofascial pain. J Pain Palliat Care Pharmacother 2004;18:15-34.
60. Affaitati G, Fabrizio A, Savini A, et al. A randomized, controlled study comparing a lidocaine patch, a placebo patch, and anesthetic injection for treatment of trigger points in patients with myofascial pain syndrome: evaluation of pain and somatic pain thresholds. Clin Ther 2009;31:705-20.
61. Burch F, Codding C, Patel N, et al. Lidocaine patch 5% improves pain, stiffness, and physical function in osteoarthritis pain patients. A prospective, multicenter, open-label effectiveness trial. Osteoarthritis Cartilage 2004;12:253-5.
62. Galer BS, Sheldon E, Patel N, et al. Topical lidocaine patch 5% may target a novel underlying pain mechanism in osteoarthritis. Curr Med Res Opin 2004;20:1455-8.
63. Gammaitoni AR, Galer BS, Onawola R, et al. Lidocaine patch 5% and its positive impact on pain qualities in osteoarthritis: results of a pilot 2-week, open-label study using the Neuropathic Pain Scale. Curr Med Res Opin 2004;20(Suppl 2):S13-19.
64. Hines R, Keaney D, Moskowitz MH, et al. Use of lidocaine patch 5% for chronic low back pain: a report of four cases. Pain Med 2002;3:361-5.
65. Galer BS, Gammaitoni AR, Oleka N, et al. Use of the lidocaine patch 5% in reducing intensity of various pain qualities reported by patients with low-back pain. Curr Med Res Opin 2004;20(Suppl 2):S5-12.
66. Gimbel J, Linn R, Hale M, et al. Lidocaine patch treatment in patients with low back pain: results of an open-label, nonrandomized pilot study. Am J Ther 2005;12:311-19.
67. Lin PL, Fan SZ, Huang CH, et al. Analgesic effect of lidocaine patch 5% in the treatment of acute herpes zoster: a double-blind and vehicle-controlled study. Reg Anesth Pain Med 2008;33:320-5.
68. Kim KH. Use of lidocaine patch for percutaneous endoscopic lumbar discect-omy. Korean J Pain 2011;24:74-80.
69. Laird JMA, Carter AJ, Grauert M, et al. Analgesic activity of a novel use-dependent sodium channel blocker, crobenetine, in mono-arthritic rats. Br J Pharmacol 2001;134:1742-8.
70. Arendt-Nielsen L, Nie H, Laursen MB, et al. Sensitization in patients with painful knee osteoarthritis. Pain 2010;149:573-81.
71. Bajaj P, Bajaj P, Graven-Nielsen T, et al. Osteoarthritis and its association with muscle hyperalgesia: an experimental controlled study. Pain 2001;93:107-14.
72. Freynhagen R, Baron R. The evaluation of neuropathic components in low back pain. Curr Pain Headache Rep 2009;13:185-90.
73. Katz NP, Gammaitoni AR, Davis MW, et al. Lidocaine patch 5% reduces pain intensity and interference with quality of life in patients with postherpetic neuralgia: an effectiveness trial. Pain Med 2002;3:324-32.
74. Überall MA, Müller-Schwefe GHH. Patient perceptions associated with the lidocaine patch 5% in daily practice. Curr Med Res Opin 2012; 28(6) 1-9.
75. Müller-Schwefe G, Zenz M (eds.) The German Pain Questionnaire. German Pain Association, 2006. ISBN: 3-00-017-440-0 (in German)
76. Hans G, Sabatowski R, Binder A, et al. Efficacy and tolerability of a 5% lidocaine medicated plaster for the topical treatment of post-herpetic neuralgia: results of a long-term study. Curr Med Res Opin 2009;25:1295-305.
77. Delorme C, Navez ML, Legout V, et al. Treatment of neuropathic pain with 5% lidocaine-medicated plaster: five years of clinical experience. Pain Res Manage 2011;16:259-62.
78. Galer BS, Gammaitoni AR. More than 7 years of consistent neuropathic pain relief in geriatric patients. Arch Intern Med 2003;163:628 (letter).
79. Wolff RF, Bala MM, Westwood M, et al. 5% lidocaine medicated plaster in painful diabetic peripheral neuropathy (DPN): a systematic review. Swiss Med Wkly 2010;140:297-306.
80. Müller-Schwefe GHH, Überall MA. Pain and quality of life (in German). Gesundh Ökon Qual Manag 2011; 16:S20-2.
81. O'Connor AB. Neuropathic pain. Quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics 2009;27:95-112.